Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Oncology|March 5, 2024
Nesprin1 Deficiency Is Associated with Poor Prognosis of Renal Cell Carcinoma and Resistance to Sunitinib TreatmentTakafumi Fukushima, Kohei Kobatake, Kento Miura, et al.
Clinical Genitourinary Cancer|May 18, 2026
Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset AnalysisTomoya Hatayama, Yohei Sekino, Go Kobayashi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 30, 2022
Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitorsKenshiro Takemoto, Yohei Sekino, Hiroyuki Kitano, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 11, 2025
Influence of best objective response to first-line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotinKohei Kobatake, Keisuke Goto, Yuki Sakamoto, et al.
Prostate International|December 15, 2025
Treatment outcomes with radium-223 in patients with metastatic castration-resistant prostate cancer with bone metastasis in real-world practice: a multiinstitutional studyHiroyuki Kitano, Kunihiro Hashimoto, Yasuhisa Hasegawa, et al.
The Prostate|January 26, 2026
Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases AnalysisTomoya Hatayama, Yohei Sekino, Go Kobayashi, et al.
International Cancer Conference Journal|June 1, 2019
Serous adenocarcinoma of retroperitoneum: a case reportYuki Kohada, Jun Teishima, Yui Hattori, et al.
The Prostate|December 23, 2025
Combining Prostate-Specific Antigen Density With PI-RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion-Targeted Re-BiopsyYuto Ono, Yuki Kohada, Shinsaku Tasaka, et al.
Oncology|February 15, 2021
BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell CarcinomaYohei Sekino, Xiangrui Han, Go Kobayashi, et al.
Urologic Oncology|June 5, 2026
Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinomaTomoya Hatayama, Yohei Sekino, Takashi Babasaki, et al.
Pageof 11